OpenAtlas Opportunity Score 87/100
RFA-RM-27-013
NIH PRIMED-AI Model-to-Clinic (RFA-RM-27-013)
NIH Common Fund PRIMED-AI opportunity to move technically validated, AI-enabled, image-centered multimodal clinical decision-support prototypes toward multi-site clinical application and adoption. Earliest submission date is September 19, 2026; applications are due October 19, 2026 at 5:00 PM applicant-local time.
FundingNIH anticipates 6-8 awards. Direct-cost limits are $450,000 per year in the UG3 phase and $1,000,000 per year in the UH3 phase.
DeadlineEarliest submission date September 19, 2026. Application due October 19, 2026 at 5:00 PM local time of the applicant organization. Late applications are not accepted.
Last verifiedOctober 1, 2026
Required next actionReview RFA-RM-27-013, confirm the project begins with a qualifying validated prototype and appropriate implementation team, complete the required attachments and budget, and submit by October 19, 2026 at 5:00 PM local time of the applicant organization.
Broad Eligibility
M2C requires an existing technically validated AI-powered, image-centered multimodal CDS prototype and a multi-institutional team capable of real-world clinical implementation and multi-site validation. An industrial partner is not mandatory, but the commercial/business component and all required clinical, AI, medical-device and workflow expertise must be identified in the application.
Atlas Analysis
NIH's PRIMED-AI Model-to-Clinic opportunity supports projects that move validated image-centered multimodal AI clinical decision-support prototypes toward real-world clinical use. NIH anticipates six to eight awards, with direct-cost limits of $450,000 per year in the UG3 phase and $1,000,000 per year in the UH3 phase.
The NIH Common Fund has posted RFA-RM-27-013, PRIMED-AI Model-to-Clinic (M2C). M2C is designed to translate technically validated AI-enabled, image-centered, multimodal clinical decision-support tools, developed toward Software as a Medical Device, into real-world clinical applications.
Timing: the earliest submission date is September 19, 2026. Applications are due October 19, 2026 at 5:00 PM local time of the applicant organization, and late applications are not accepted.
Funding: NIH anticipates approximately six to eight awards. Direct-cost limits are $450,000 per year during the UG3 phase and $1,000,000 per year during the UH3 phase. The combined UG3/UH3 project period cannot exceed five years. Cost sharing is not required.
Entry threshold: projects without an existing AI-powered, image-centered, multimodal CDS prototype are non-responsive. NIH states that a technically validated prototype may have validation at a minimum of a single site, unimodally or in retrospective data, but the model must already exist and be image-centered. The UH3 phase requires multi-site clinical validation. Applicants must also demonstrate sufficient access to verified, comprehensive multimodal datasets.
Atlas fit: N9+ may be relevant as a complementary physiologic, remote-exam, connected-health or workflow data source inside a qualified multimodal CDS implementation, but N9+ cannot be the required imaging anchor and cannot substitute for an existing AI prototype. The most realistic Atlas pathway is technology-subcontract or joint participation with a team that already owns a validated imaging-centered AI model and needs additional clinical data, remote-exam workflows or deployment infrastructure.
Applications may be prepared through NIH ASSIST, an institutional system-to-system solution, or Grants.gov Workspace, with eRA Commons used for tracking. Verify current NIH notices and PRIMED-AI FAQs before submission.
Source verificationOfficial government source · commonfund.nih.govAtlas last verified this record October 1, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
